EA015461B1 - Применение пробиотических бактерий в пищевых, кормовых и лечебных продуктах - Google Patents

Применение пробиотических бактерий в пищевых, кормовых и лечебных продуктах Download PDF

Info

Publication number
EA015461B1
EA015461B1 EA200800913A EA200800913A EA015461B1 EA 015461 B1 EA015461 B1 EA 015461B1 EA 200800913 A EA200800913 A EA 200800913A EA 200800913 A EA200800913 A EA 200800913A EA 015461 B1 EA015461 B1 EA 015461B1
Authority
EA
Eurasian Patent Office
Prior art keywords
probiotic
product
probiotic bacteria
bacillus
group
Prior art date
Application number
EA200800913A
Other languages
English (en)
Russian (ru)
Other versions
EA200800913A1 (ru
Inventor
Кайса Олсон
Маргит Махлапуу
Улла Свенссон
Original Assignee
Арла Фудз Амба
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37943064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA015461(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Арла Фудз Амба filed Critical Арла Фудз Амба
Publication of EA200800913A1 publication Critical patent/EA200800913A1/ru
Publication of EA015461B1 publication Critical patent/EA015461B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • A61K2035/115Probiotics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225Lactobacillus
    • C12R2001/23Lactobacillus acidophilus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225Lactobacillus
    • C12R2001/245Lactobacillus casei
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87Re-use of by-products of food processing for fodder production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA200800913A 2005-10-07 2006-10-02 Применение пробиотических бактерий в пищевых, кормовых и лечебных продуктах EA015461B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502214A SE529185C2 (sv) 2005-10-07 2005-10-07 Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
PCT/SE2006/001117 WO2007043933A1 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity

Publications (2)

Publication Number Publication Date
EA200800913A1 EA200800913A1 (ru) 2008-10-30
EA015461B1 true EA015461B1 (ru) 2011-08-30

Family

ID=37943064

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800913A EA015461B1 (ru) 2005-10-07 2006-10-02 Применение пробиотических бактерий в пищевых, кормовых и лечебных продуктах

Country Status (16)

Country Link
US (1) US20080267933A1 (https=)
EP (2) EP1945235B1 (https=)
JP (1) JP2009511469A (https=)
CN (1) CN101287478B (https=)
AU (1) AU2006299956B2 (https=)
BR (1) BRPI0616993A2 (https=)
CA (1) CA2624890A1 (https=)
CY (1) CY1113704T1 (https=)
DK (2) DK2431044T3 (https=)
EA (1) EA015461B1 (https=)
ES (2) ES2396865T3 (https=)
PL (1) PL1945235T3 (https=)
PT (1) PT1945235E (https=)
SE (1) SE529185C2 (https=)
SI (1) SI1945235T1 (https=)
WO (1) WO2007043933A1 (https=)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007085970A2 (en) * 2006-01-27 2007-08-02 Danisco A/S Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders
JP5229977B2 (ja) * 2006-09-08 2013-07-03 雪印メグミルク株式会社 血中アディポネクチン濃度増加促進及び/又は減少抑制剤
US9084434B2 (en) * 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
EP2011506A1 (en) 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
BRPI0721863A2 (pt) * 2007-07-25 2014-02-18 Danisco Composição para induzir ou melhorar a sensação de satisfação e/ou saciedade, método para identificar e/ou isolar bactérias que são capazes de induzir ou melhorar satisfação e/ou saciedade, cepa bacteriana, uso de uma cepa bacteriana, e, método para preparar um alimento, suplemento alimentício ou composição alimetícia que melhora satisfação e/ou saciedade.
EP2030623A1 (en) * 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
JP5225652B2 (ja) * 2007-10-29 2013-07-03 雪印メグミルク株式会社 アディポネクチン分泌促進及び/又は減少抑制剤
AU2008333718B2 (en) 2007-12-06 2012-03-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage
FR2930264B1 (fr) * 2008-04-18 2013-02-22 Gervais Danone Sa Nouvelle souche de lactobacillus paracasei subsp. paracasei dotee de proprietes antimicrobiennes et immunomodulatrices.
EP2123168B1 (en) * 2008-05-16 2011-12-21 Nestec S.A. Lactobacillus paracasei and weight control
WO2009142713A1 (en) * 2008-05-19 2009-11-26 Nestec S.A. Methods for reducing lipid absorption by an animal
AU2009282482B2 (en) * 2008-08-15 2015-11-26 Société des Produits Nestlé S.A. Methods for enhancing energy metabolism
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
CA2753083C (en) * 2009-03-06 2021-04-20 Federation Des Producteurs Acericoles Du Quebec Symbiotic maple product compositions and methods
EP2407170B1 (en) * 2009-03-10 2015-03-25 Jinis Biopharmaceuticals Co. Prevention and treatment of obesity and metabolic diseases induced by obesity using microorganisms
US20120027737A1 (en) 2009-03-25 2012-02-02 Chr-Hansen A/S Use of probiotics to ameliorate diet-induced insulin resistance
DK2411027T3 (en) * 2009-03-25 2015-01-19 Chr Hansen As USING a probiotic ADJUSTING body weight
WO2010114864A1 (en) * 2009-04-01 2010-10-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
FI123157B (fi) * 2009-05-12 2012-11-30 Valio Oy Probioottien uusi käyttö
EP3181134B1 (en) 2009-06-19 2019-10-30 DuPont Nutrition Biosciences ApS Bifidobacteria for treating diabetes and related conditions
JP5436991B2 (ja) * 2009-09-10 2014-03-05 国立大学法人北海道大学 ラクトバチルス・プランタラムの菌体又は培養物を有効成分とするインスリン抵抗性改善剤
EP2308499A1 (en) * 2009-09-30 2011-04-13 Nestec S.A. Bifidobacterium longum ATCC BAA-999 (BL999) and weight control
CN107574131A (zh) 2009-11-11 2018-01-12 营养健康有限公司 益生菌双歧杆菌菌株
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
NL2004200C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
KR101873193B1 (ko) * 2010-06-08 2018-07-02 아사히 그룹 홀딩스 가부시키가이샤 지질 대사 개선제
ES2389547B1 (es) * 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
ITMI20111488A1 (it) 2011-08-03 2013-02-04 Gnosis Spa Formulazioni comprendenti saccharomyces boulardii e superossido dismutasi (sod) per controllare l'obesita'
US9636367B2 (en) * 2011-10-18 2017-05-02 Nestec S.A. Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
EP2925333A1 (en) 2012-11-12 2015-10-07 Compagnie Gervais Danone Lactobacillus rhamnosus strain for reducing body fat accumulation
MY183171A (en) * 2013-04-17 2021-02-18 Suntory Holdings Ltd Composition containing bacterium belonging to genus lactobacillus
ES2526986B1 (es) 2013-07-18 2015-11-02 Biopolis, S.L. Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas
KR101535077B1 (ko) * 2013-09-13 2015-07-08 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 가지는 비피도박테리움 락티스 hy8101 및 이를 유효성분으로 함유하는 제품
KR101545551B1 (ko) 2013-12-12 2015-08-19 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
WO2015121458A2 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
US20160354418A1 (en) * 2014-02-14 2016-12-08 Vesale Pharma Sa Use of compositions comprising bifidobacterium animalis ssp. lactis lmg p-28149
BE1000016B1 (fr) * 2014-04-25 2016-02-01 Vesale Pharma Nv Composition comprenant du bifidobacterium animalis ssp. lactis.
WO2015121455A1 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant au moins un probiotique
BE1000017B1 (fr) * 2014-04-25 2016-01-21 Vesale Pharma Nv Composition comprenant au moins un probiotique
MX2017001734A (es) * 2014-08-08 2017-04-27 Nestec Sa Mioinositol y probioticos y usos.
CN104186655B (zh) * 2014-08-27 2016-06-29 内蒙古伊利实业集团股份有限公司 具有降血脂及抗氧化功能的低脂发酵乳及其制备方法
KR101604212B1 (ko) * 2015-07-17 2016-03-17 울산대학교 산학협력단 Nad를 함유하는 비만 또는 내당능장애의 예방 및 치료용 조성물
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
CN109312297B (zh) * 2015-12-11 2022-09-23 精密生物集团有限公司 用于治疗肥胖症和相关代谢病的干酪乳杆菌
KR20220001516A (ko) * 2016-04-14 2022-01-05 듀폰 뉴트리션 바이오사이언시즈 에이피에스 식품, 에너지 및/또는 지방 섭취 감소를 위한 비피더스균
CN109089421A (zh) 2017-02-10 2018-12-25 完美(中国)有限公司 新型双歧杆菌益生菌菌株
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
TWI640313B (zh) * 2017-08-18 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於抑制肥胖之用途
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health
FR3095761B1 (fr) 2019-05-06 2023-11-10 Lab Attitude Composition nutraceutique pour induire une perte de poids et réduire la graisse abdominale
AU2020412749A1 (en) 2019-12-27 2022-06-16 Biopolis, S.L. Uses of lipoteichoic acid from Bifidobacteria
CN111587952A (zh) * 2020-05-27 2020-08-28 佛山科学技术学院 一种降低家犬体脂沉积的益生菌添加剂
JP7718672B2 (ja) * 2020-12-25 2025-08-05 日清食品株式会社 腸溶コーティング錠
KR102616412B1 (ko) * 2021-07-30 2023-12-21 주식회사 메디오젠 비피도박테리움 애니말리스 락티스 mg741 균주를 포함하는 비만 또는 비알콜성 지방간 예방 또는 치료용 조성물
FR3125945B1 (fr) 2021-08-03 2024-07-12 Setalg Composition pour protéger un microorganisme dans un environnement acide.
KR102445708B1 (ko) 2021-12-02 2022-09-23 일동바이오사이언스(주) 비피도박테리움 락티스 idcc 4301을 포함하는 체지방감소용 조성물
CN118716406A (zh) * 2024-04-30 2024-10-01 卡士乳业(深圳)有限公司 含活性乳双歧杆菌的发酵乳在调节亚健康人群状态中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029833A1 (en) * 1997-12-08 1999-06-17 Arlafoods Amba Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain
WO2004014403A1 (en) * 2002-08-09 2004-02-19 Bioneer Corporation Microorganisms for inhibiting obesity and diabetes mellitus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61109729A (ja) * 1984-11-05 1986-05-28 Advance Res & Dev Co Ltd コレステロ−ル低下剤
JPS61271223A (ja) * 1985-05-24 1986-12-01 Biofuerumin Seiyaku Kk 血中脂質改善剤
JPH0696537B2 (ja) * 1986-05-02 1994-11-30 雪印乳業株式会社 血清コレステロ−ル上昇抑制剤
JP2992945B2 (ja) * 1994-03-11 1999-12-20 カルピス株式会社 ラクトバチルス・アシドフィルス乳酸菌
JPH107577A (ja) * 1996-06-17 1998-01-13 Yakult Honsha Co Ltd 血糖降下剤
US6641808B1 (en) 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
JP2001097870A (ja) * 1999-09-30 2001-04-10 Snow Brand Milk Prod Co Ltd 乳酸菌を利用した胆汁酸の吸着方法
JP2001292728A (ja) 2000-04-13 2001-10-23 Enajikku Kk 肥満防止食品
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US6963306B2 (en) * 2001-02-02 2005-11-08 Rosum Corp. Position location and data transmission using pseudo digital television transmitters
EP1344458A1 (en) * 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
US6565847B1 (en) 2002-07-03 2003-05-20 Vitacost.Com, Inc. Thermogenic weight management composition
US20040014403A1 (en) * 2002-07-16 2004-01-22 Oberkampf Brandon L. CMP point of use filtration
US20070098705A1 (en) * 2003-05-22 2007-05-03 Symbiotics Ab Probiotic composition comprising at least two lactic acid bacterial strains which are able to clonise the gatrointestonal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and fiber fermenting property
SE0400355D0 (sv) * 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
AU2008333718B2 (en) * 2007-12-06 2012-03-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029833A1 (en) * 1997-12-08 1999-06-17 Arlafoods Amba Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain
WO2004014403A1 (en) * 2002-08-09 2004-02-19 Bioneer Corporation Microorganisms for inhibiting obesity and diabetes mellitus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KALAVATHY, R. ET AL., "Effects of Lactobacillus cultures on growth performance, abdominal fat deposition, serum lipids and weight of organs of broiler chickens", British Poultry Science, 2003, vol. 44, page 139 - page 144, page 141, column 2, paragraph 2 - page 142, column 1, paragraph 1, abstract *
MATSUZAKI, TAKESHI ET AL., "Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei", APMIS, 1997, vol. 105, no. 8, page 643 - page 649, page 647, column 2 - page 648, column 1, abstract *
TABUCHI, MIHOKO ET AL., "Antidiabetic Effect of Lactobacillus GG in Streptozotocin-induced Diabetic Rats", Biosci. Biotechnol. Biochem., 2003, vol. 67, no. 6, page 1421 - page 1424, page 1423, column 2, paragraph 2, figure 1B, 2, abstract *

Also Published As

Publication number Publication date
EA200800913A1 (ru) 2008-10-30
CA2624890A1 (en) 2007-04-19
DK2431044T3 (en) 2016-04-11
CY1113704T1 (el) 2016-06-22
EP1945235A1 (en) 2008-07-23
CN101287478A (zh) 2008-10-15
SI1945235T1 (sl) 2013-02-28
ES2567404T3 (es) 2016-04-22
WO2007043933A1 (en) 2007-04-19
CN101287478B (zh) 2012-10-03
JP2009511469A (ja) 2009-03-19
US20080267933A1 (en) 2008-10-30
SE0502214L (sv) 2007-04-08
AU2006299956B2 (en) 2012-03-15
AU2006299956A1 (en) 2007-04-19
DK1945235T3 (da) 2013-01-14
SE529185C2 (sv) 2007-05-22
ES2396865T3 (es) 2013-02-28
EP2431044A1 (en) 2012-03-21
EP2431044B1 (en) 2016-01-13
BRPI0616993A2 (pt) 2011-07-05
EP1945235B1 (en) 2012-09-26
EP1945235A4 (en) 2009-11-11
PT1945235E (pt) 2013-01-14
PL1945235T3 (pl) 2013-03-29

Similar Documents

Publication Publication Date Title
EA015461B1 (ru) Применение пробиотических бактерий в пищевых, кормовых и лечебных продуктах
EP2442814B1 (en) Bifidobacteria for treating diabetes and related conditions
TWI572354B (zh) 抑制發炎之組成物
EP3442549B1 (en) Bifidobacteria for increasing lean body mass
EP3478305A1 (en) Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal
EP4358983A1 (en) Method for favoring wellness and facilitating self-control before, during and/or after a restrictive diet
CN106852938A (zh) 拟杆菌(Bacteroides)在治疗和预防肥胖相关疾病中的应用
CN106974262A (zh) 肠道益生杆菌在治疗和预防肥胖及其相关疾病中的应用
CN109069554A (zh) 用于降低食物、能量和/或脂肪摄入的双歧杆菌
WO2026043077A1 (ko) 근 감소증 개선용 혼합균주 및 이를 포함하는 조성물
Arora et al. Therapeutic potential of probiotics: A ray of hope or nightmare?
US11389487B2 (en) Streptococcus australis as a biotherapeutic
Pande et al. Prospectus of probiotics in modern age diseases
KR101809616B1 (ko) 항비만효과를 가지는 케피어 유래 프로바이오틱 균주
WO2023079036A1 (en) Probiotic composition comprising a lactobacillus salivarius strain, a lactobacillus camelliae strain and a bifidobacterium ruminantium strain
Reehana et al. Synbiotics in Nutrition
KR20230045340A (ko) 체지방을 감소시키거나 지방간 형성을 억제시키기 위한 열처리 락토바실러스 플란타룸 k8 조성물
JP2025131333A (ja) 細胞老化抑制用組成物
Das et al. Metabolic and potential health benefits of nutraceuticals on gut microbiome
AR et al. Probiotic: a rational approach to use Probiotic as medicine
HK1239564A1 (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases
HK1146914B (en) Pharmaceutical compositions comprising l. acidophilus and bifidobacterium lactis for use in the treatment of functional bowel disorder
HK1146914A1 (en) Pharmaceutical compositions comprising l. acidophilus and bifidobacterium lactis for use in the treatment of functional bowel disorder

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU